Oral contraceptive use is associated with prostate cancer: An ecological study - Abstract

Division of Urologic Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.


Several recent studies have suggested that oestrogen exposure may increase the risk of prostate cancer (PCa).

To examine associations between PCa incidence and mortality and population-based use of oral contraceptives (OCs). It was hypothesised that OC by-products may cause environmental contamination, leading to an increased low level oestrogen exposure and therefore higher PCa incidence and mortality.

The hypothesis was tested in an ecological study. Data from the International Agency for Research on Cancer were used to retrieve age-standardised rates of prostate cancer in 2007, and data from the United Nations World Contraceptive Use 2007 report were used to retrieve data on contraceptive use. A Pearson correlation and multivariable linear regression were used to associate the percentage of women using OCs, intrauterine devices, condoms or vaginal barriers to the age standardised prostate cancer incidence and mortality. These analyses were performed by individual nations and by continents worldwide.

OC use was significantly associated with prostate cancer incidence and mortality in the individual nations worldwide (r=0.61 and r=0.53, respectively; p< 0.05 for all). PCa incidence was also associated with OC use in Europe (r=0.545, p< 0.05) and by continent (r=0.522, p< 0.05). All other forms of contraceptives (ie, intra-uterine devices, condoms or vaginal barriers) were not correlated with prostate cancer incidence or mortality. On multivariable analysis the correlation with OC was independent of a nation's wealth.

A significant association between OCs and PCa has been shown. It is hypothesised that the OC effect may be mediated through environmental oestrogen levels; this novel concept is worth further investigation.

Written by:
Margel D, Fleshner NE.   Are you the author?

Reference: BMJ Open. 2011 Nov 14;1(2):e000311.
doi: 10.1136/bmjopen-2011-000311

PubMed Abstract
PMID: 22102643

UroToday.com Prostate Cancer Section